Context
Founded in 1997 by Dr. h.c. Thomas Straumman, Medartis Holding AG headquartered in Basel, Switzerland, is a leading manufacturer and provider of medical devices for internal surgical bone fixation.
Medartis specializes in fixation solutions that comprise technical high-precision titanium screws, plates, and surgical instruments for bone fractures fixation and osteotomies of the hand, wrist, elbow, foot, ankle as well as the head.
The company sells its products in 44 countries - including Switzerland, Germany, France, the United States, Japan, Australia and Brazil - directly through its headquarters and 11 subsidiaries, and via distributors.
The funds will in particular help intensify commercialization efforts in the US in order to accelerate growth and increase the market share as well as sustain the commercial launch of products in new territories, including Japan and China.
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures and osteotomies for the craniofacial region as well as for upper and lower extremities. Medartis employs over 480 individuals across its 11 locations, and Medartis products are sold in 44 countries globally. For patients’ welfare, Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best in class services that represent advances in osteosynthesis.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Medartis’ IPO CHF142.6 million on SIX Swiss Exchange
Bryan, Garnier & Co acted as Joint Global Coordinator and Joint Bookrunner on this landmark Swiss IPO.
Offer multiple times over-subscribed across the price range, given strong demand across Switzerland, Continental Europe, UK and the U.S.
Final offer price of CHF48 per share, approximate mid-point of CHF44 – CHF54 price range.
The offering of approximately CHF123.9 million (CHF142.6 million including fully exercised 15% over-allotment shares) consisted of ca. 2.99 million newly issued shares.
Implied market cap of CHF563 million at IPO.
Share